Immunochemistry News and Research

RSS

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way.

17 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

TJUH adopts new equipment from Roche Diagnostics for laboratory testing services

Thomas Jefferson University Hospital (TJUH) is advancing its laboratory testing services with new state-of-the-art equipment from Roche Diagnostics designed to help labs increase their testing capacity and deliver reliable results with greater efficiency.

From Roche Sequencing and Life Science 20 Sep 2011

FDA approves first scorpion antivenom

The U.S. Food and Drug Administration today approved Anascorp-, an antivenom produced in Mexico and tested in clinical trials conducted through the University of Arizona, for use in treating patients suffering the effects of scorpion sting.

5 Aug 2011

FDA clears BG Medicine's Galectin-3 test to identify high risk patients with cardiovascular disease

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company's Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

23 Nov 2010

Roche granted FDA 510(k) clearance for cobas 8000 modular analyzer series

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® 8000 modular analyzer series, a Serum Work Area solution designed for diagnostic laboratories with a workload of 3-15 million clinical chemistry / immunochemistry tests per year.

From Roche Sequencing and Life Science 14 Sep 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Pressure BioSciences signs CRADA with AFIP, ARP and VA

Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").

27 May 2010

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

PPD, Inc. (Nasdaq: PPDI) today announced it is launching the PPD Vaccines & Biologics Center of Excellence, a first-in-kind comprehensive network of integrated, world-class laboratory services focused specifically on vaccine and biologic drug development.

24 Mar 2010

PAREXEL International, Proteome Sciences form biomarker alliance

PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Proteome Sciences plc, a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development. PAREXEL is using Proteome Sciences' PS Biomarker Services™ protein and peptide biomarker capabilities to support biopharmaceutical companies in making earlier assessments of new compounds in development.

From Parexel 11 Feb 2010

Researchers describe how PDNF protein prolongs the life of T. cruzi parasite

The parasite Trypanosoma cruzi (or T. cruzi), which causes Chagas' disease, will go to great lengths to evade death once it has infected human host cells, researchers have discovered. In a study published in the November 17 online issue of Science Signaling, the researchers describe how a protein called parasite-derived neurotrophic factor (PDNF) prolongs the life of the T. cruzi parasite by activating anti-apoptotic (or anti-cell-death) molecules in the host cell. These protective mechanisms help to explain how host cells continue to survive despite being exploited by T. cruzi parasites.

9 Dec 2009

Roche Diagnostics launches new customer training center in Pleasanton, California

Roche Diagnostics announced today the opening of a new west-coast customer training center in Pleasanton, California, as part of an initiative to make state-of-the-art training on diagnostic equipment more accessible to hospitals and independent laboratories on the west and east coasts.

From Roche Sequencing and Life Science 8 Dec 2009

Abbott and BG Medicine announce a development and commercialization agreement for galectin-3 biomarker

Abbott and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry instrument platform, specifically the company's i1000SR and i2000SR instruments. The agreement grants Abbott a license to BG Medicine's intellectual property related to galectin-3.

17 Nov 2009

Research study on EGFR and HER2 expressions in BTC

The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others.

19 Oct 2009

PharmaNet Development to display innovative solutions at 2009 AAPS Annual Meeting and Exposition

PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the Company and its subsidiaries Anapharm and Taylor Technology will be showcasing a range of innovative solutions at the 2009 AAPS Annual Meeting and Exposition.

13 Oct 2009

Scientists create monoclonal antibody libraries against avian influenza

An international group of American and Turkish research scientists, led by Sea Lane Biotechnologies, has created the first comprehensive monoclonal antibody libraries against avian influenza (H5N1) using samples from survivors of the 2005/2006 "bird flu" outbreak in Turkey.

15 Apr 2008